Imaging of somatostatin receptors by indium-111-pentetreotide correlates with quantitative determination of somatostatin receptor type 2 gene expression in neuroblastoma tumors

Clinical Cancer Research

Volumn 3, Issue 12 I, 1997, Pages 2385-2391

  Briganti, Vittorio ^a   Sestini, Roberta ^a   Orlando, Claudio ^a   Bernini, Gabriella ^a   La Cava, Giuseppe ^a   Tamburini, Angela ^a   Raggi, Claudia Casini ^a   Serio, Mario ^a   Maggi, Mario ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PENTETREOTIDE IN 111; RECEPTOR SUBTYPE; SOMATOSTATIN RECEPTOR;

ARTICLE; BRAIN SCINTISCANNING; CHILD; CLINICAL ARTICLE; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DRUG RECEPTOR BINDING; FEMALE; HUMAN; INFANT; ISOTOPE LABELING; MALE; NEUROBLASTOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECEPTOR DENSITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADOLESCENT; ADRENAL GLAND NEOPLASMS; ADULT; ANEUPLOIDY; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 1; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; HUMANS; INDIUM RADIOISOTOPES; INFANT; MALE; NEOPLASM STAGING; NEUROBLASTOMA; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SOMATOSTATIN; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0031418445     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Lamberts, S. W. J., Koper, J. W., and Reubi, J-C. Potential role of somatostatin analogues in the treatment of cancer. Eur. J. Clin. Invest., 17: 281-287, 1987.
2. Krenning, E. P., Breeman, W. A. P., Kooij, P. P. M., Lameris, J. S., Bakker, W. H., Koper, J. W., Ausema, L., Reubi, J-C., and Lamberts, S. W. J. Localization of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet, 1: 242-244, 1989.
3. 125I-Tyr3]octreotide: the Rotterdam experience with more than 1000 patients. Eur. J. Nucl. Med., 20: 716-731, 1993.
4. Reubi, J. C., and Torhorst, J. Relationship between somatostatin, EGF- and steroid-hormone-receptors in breast cancer. Cancer (Phila.), 64: 1254-1260, 1989.
5. Foekens, J. A., Portengen, H., van Putten, W. L. J., Trapman, A. M. A. C., Reubi, J-C., Alexieva-Figuch, J., and Klijn, J. G. M. Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res., 49: 7002-7009, 1989.
6. Moertel, C. L., Reubi, J-C., Scheithauer, B. S., Schaid, D. J., and Kvols, L. K. Expression of somatostatin receptors in childhood neuroblastoma. Am. J. Clin. Pathol., 102: 752-756, 1994.
7. O'Dorisio, M. S., Chen, F., O'Dorisio, T. M., Wray, D., and Qualman, S. J. Characterization of somatostatin receptors in human neuroblastoma tumors. Cell Growth Differ., 5: 1-8, 1994.
8. Maggi, M., Baldi, E., Finetti, G., Franceschelli, F., Brocchi, A., Lanzillotti, R., Serio, M., Camboni, M. G., and Thiele, C. J. Identification, characterization, and biological activity of somatostatin receptors in human neuroblastoma cell lines. Cancer Res., 54: 124-133, 1994.
9. Manil, L., Edeline, V., Lumbroso, J., Lequen, H., and Zucker, J. M. Indium-111-pentetreotide scintigraphy in children with neuroblast-derived tumors. J. Nucl. Med., 37: 893-896, 1996.
10. Lamberts, S. W. J., Krenning, E. P., and Reubi, J-C. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr. Rev., 12: 450-482, 1991.
11. Raulf, F., Perez, J., Hoyer, D., and Bruns, C. Differential expression of five somatostatin receptor subtypes, SSTR1-5, in the CNS and peripheral tissue. Digestion, 55 (Suppl. 3): 46-53, 1994.
12. Reisine, T., and Bell, G. I. Molecular biology of somatostatin receptors. Endocr. Rev., 16: 427-442, 1995.
13. Buscail, L., Saint-Laurent, N., Chastre, E., Vaillant, J-C., Gespach, C., Capellà, G., Kalthoff, H., Lluis, F., Vaysse, N., and Susini, C. Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res., 56: 1823-1827, 1996.
14. Reubi, J. C., Waser, B., Schaer, J-C., and Markwalder, R. Somatostatin receptors in human prostate and prostate cancer. J. Clin. Endocrinol. Metab., 80: 2806-2814, 1995.
15. Friess, H., Buchler, M., Beglinger, C., Weber, A., Kunz, J., Fritsch, K., Dennler, H. J., and Beger, H. G. Low-dose octreotide treatment is not effective in patients with advanced pancreatic cancer. Pancreas, 5: 540-545, 1993.
16. Epelbaum, J., Bertherat, J., Prévost, G., Kordon, C., Meyerhof, W., Wulfsen, I., Richter, D., and Plouin, P-F. Molecular and pharmacological characterization of somatostatin receptor subtypes in adrenal, extradrenal, and malignant pheochromocytomas. J. Clin. Endocrinol. Metab., 80: 1837-1844, 1995.
17. Kubota, A., Yamada, Y., Kagimoto, S., Shimatsu, A., Imamura, M., Tsuda, K., and Imura, H. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J. Clin. Invest., 93: 1321-1325, 1994.
18. Reubi, J-C., Schaer, J. C., Waser, B., and Mengod, G. Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res., 54: 3455-3459, 1994.
19. Prévost, G., Veber, N., Viollet, C., Roubert, V., Roubert, P., Bérnard, J., and Eden, P. Somatostatin-14 mainly binds the somatostatin receptor subtype 2 in the human neuroblastoma tumors. Neuroendocrinology, 63: 188-197, 1996.
20. Sestini, R., Orlando, C., Peri, A., Tricarico, C., Pazzagli, M., Serio, M., Pagani, A., Bussolati, G., Granchi, S., and Maggi, M. Quantitation of somatostatin receptor type 2 gene expression in neuroblastoma cell line and primary tumors using competitive reverse transcription-polymerase chain reaction. Clin. Cancer Res., 2: 1757-1765, 1996.
21. Seeger, R. C., Brodeur, G. M., Sather, H., Dalton, A., Siegel, S. E., Wong, K. Y., and Hammond, D. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N. Engl. J. Med., 318: 1111-1116, 1985.
22. Briganti, V., Mannelli, M., La Cava, G., Peri, A., Meldolesi, U., Masi, R., and Pupi, A. Characterization of an ectopic secreting carcinoid with 111In-[DTPA-D-Phe]-pentetreotide. J. Nucl. Med., 38: 711-714, 1997.
23. 111In-DTPA-D-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in rats. Life Sci., 49: 1593-1601, 1991.
24. Maggi, M., Barni, T., Orlando, C., Fantoni, G., Finetti, G., Vannelli, G. B., Mancina, R., Gloria, L., Bonaccorsi, L., Yanaghisawa, M., and Forti, G. Endothelin-1 and its receptors in human testis. J. Androl., 16: 213-224, 1995.
25. Sestini, R., Orlando, C., Zentilin, L., Lami, D., Gelmini, S., Pinzani, P., Giacca, M., and Pazzagli, M. Measurement of gene amplification for c-erbB-2, c-myc, epidermal growth factor receptor, int-2 and N-myc by quantitative PCR with a multiple competitor template. Clin. Chem., 41: 826-832, 1995.
26. Orlando, C., Sestini, R., Zentilin, L., Gelmini, S., Pinzani, P., Giacca, M., and Pazzagli, M. Image analysis in quantitative PCR. An application for the measurement of c-erbB-2 amplification in DNA from human tumors. J. Biolum. Chemilum., 9: 223-228, 1994.
27. Sestini, R., Orlando, C, Zentilin, L., Gelmini, S., Pinzani, P., Bianchi, S., Selli, C., Giacca, M., and Pazzagli, M. Measuring c-erbB-2 oncogene amplification in fresh and paraffin-embedded tumors by competitive polymerase chain reaction. Clin. Chem., 40: 630-636, 1994.
28. Kaplan, E., and Meier, P. Non parametric estimation from incomplete observations. J. Am. Stat. Assoc., 58: 457-481, 1958.
29. Brodeur, G. M. Molecular basis for heterogeneity in human neuroblastomas. Eur. J. Cancer, 31A: 505-510, 1995.
30. Evans, A. E., D'Angio, G. J., Propert, K., Anderson, J., and Hann, H-W. Prognostic factors in neuroblastoma. Cancer (Phila.), 59: 1853-1859, 1987.
31. Christiansen, H., Sahin, K., Berthold, F., Hero, B., Terpe, H-J., and Lampert, F. Comparison of DNA aneuploid, chromosome 1 abnormalities, MYCN amplification and CD44 expression as prognostic factors in neuroblastoma. Eur. J. Cancer, 31A: 541-544, 1995.
32. Niethammer, D., and Handgretinger, R. Clinical strategies for the treatment of neuroblastoma. Eur. J. Cancer, 31A: 568-571, 1995.
33. John, M., Meyerhof, W., Richter, D., Waser, B., Schaer, J-C., Scherubl, H., Boese-Landgraf, J., Neuhaus, P., Ziske, C., Moiling, K., Riecken, E-O, Reubi, J-C., and Wiedenmann, B. Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2. Gut, 38: 33-39, 1996.
34. Kalkner K-M., Tiensuu Janson, E., Nilsson, S., Carlsson, S., Oberg, K., and Westlin, J-E. Somatostatin receptor scintigraphy in patients with carcinoid tumors: comparison between radioligand uptake and tumor markers. Cancer Res., 55: 5801s-5804s, 1995.
35. Evans, A. E., Baum, E., and Chard, R. Do infants with stage IV-S neuroblastoma need treatments? Arch. Dis. Child., 56: 270-274, 1981.